EP2376074 - METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.01.2020 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 08.02.2019 | ||
Former | Grant of patent is intended Status updated on 17.07.2018 | ||
Former | Examination is in progress Status updated on 11.11.2016 | Most recent event Tooltip | 08.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 10.08.2022 [2022/32] | Applicant(s) | For all designated states Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG Berliner Strasse 1 12529 Schönefeld/OT Waltersdorf / DE | [2011/42] | Inventor(s) | 01 /
CLEMENT, Bernd Johann-Fleck-Str. 27 24106 Kiel / DE | 02 /
SCHADE, Dennis Hasseldieksdammer Weg 5 24114 Kiel / DE | [2011/42] | Representative(s) | Zech, Stefan Markus, et al Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB Postfach 86 06 24 81633 München / DE | [2019/11] |
Former [2011/42] | Zech, Stefan Markus, et al Meissner, Bolte & Partner GbR Postfach 86 06 24 81633 München / DE | Application number, filing date | 10706476.8 | 08.01.2010 | [2019/11] | WO2010DE00009 | Priority number, date | DE20091004204 | 09.01.2009 Original published format: DE102009004204 | [2011/42] | Filing language | DE | Procedural language | DE | Publication | Type: | A1 Application with search report | No.: | WO2010078867 | Date: | 15.07.2010 | Language: | DE | [2010/28] | Type: | A1 Application with search report | No.: | EP2376074 | Date: | 19.10.2011 | Language: | DE | The application published by WIPO in one of the EPO official languages on 15.07.2010 takes the place of the publication of the European patent application. | [2011/42] | Type: | B1 Patent specification | No.: | EP2376074 | Date: | 13.03.2019 | Language: | DE | [2019/11] | Search report(s) | International search report - published on: | EP | 15.07.2010 | Classification | IPC: | A61K31/155, C07C257/10, C07D309/28, C07C279/18, C07C257/18 | [2018/28] | CPC: |
C07C279/18 (EP,US);
C07C257/10 (KR);
A61K31/155 (KR);
A61P11/00 (EP);
A61P25/00 (EP);
A61P31/12 (EP);
A61P31/16 (EP);
A61P31/18 (EP);
A61P33/02 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
A61P7/02 (EP);
A61P9/00 (EP);
A61P9/12 (EP);
C07C217/02 (KR);
C07C257/18 (EP,US);
C07C259/12 (KR);
C07D309/28 (EP,US);
Y02A50/30 (EP)
(-)
|
Former IPC [2011/42] | A61K31/155, C07C257/10 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2019/11] | Extension states | AL | Not yet paid | BA | Not yet paid | RS | Not yet paid | Title | German: | VERFAHREN ZUR VERBESSERTEN BIOAKTIVIERUNG VON ARZNEISTOFFEN | [2011/42] | English: | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | [2011/42] | French: | PROCÉDÉ POUR AMÉLIORER LA BIOACTIVATION DE SUBSTANCES PHARMACEUTIQUES | [2011/42] | Entry into regional phase | 15.07.2011 | National basic fee paid | 15.07.2011 | Designation fee(s) paid | 15.07.2011 | Examination fee paid | Examination procedure | 15.07.2011 | Examination requested [2011/42] | 27.02.2012 | Amendment by applicant (claims and/or description) | 15.04.2013 | Despatch of a communication from the examining division (Time limit: M06) | 25.10.2013 | Reply to a communication from the examining division | 01.07.2016 | Despatch of a communication from the examining division (Time limit: M04) | 10.11.2016 | Reply to a communication from the examining division | 18.07.2018 | Communication of intention to grant the patent | 28.11.2018 | Fee for grant paid | 28.11.2018 | Fee for publishing/printing paid | 28.11.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.04.2013 | Opposition(s) | 16.12.2019 | No opposition filed within time limit [2020/08] | Fees paid | Renewal fee | 30.01.2012 | Renewal fee patent year 03 | 30.01.2013 | Renewal fee patent year 04 | 30.01.2014 | Renewal fee patent year 05 | 29.01.2015 | Renewal fee patent year 06 | 29.01.2016 | Renewal fee patent year 07 | 27.07.2017 | Renewal fee patent year 08 | 31.01.2018 | Renewal fee patent year 09 | 30.01.2019 | Renewal fee patent year 10 | Penalty fee | Additional fee for renewal fee | 31.01.2017 | 08   M06   Fee paid on   27.07.2017 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 08.01.2010 | CY | 13.03.2019 | CZ | 13.03.2019 | DK | 13.03.2019 | EE | 13.03.2019 | ES | 13.03.2019 | FI | 13.03.2019 | HR | 13.03.2019 | IT | 13.03.2019 | LT | 13.03.2019 | LV | 13.03.2019 | MC | 13.03.2019 | MK | 13.03.2019 | MT | 13.03.2019 | NL | 13.03.2019 | PL | 13.03.2019 | RO | 13.03.2019 | SE | 13.03.2019 | SI | 13.03.2019 | SK | 13.03.2019 | SM | 13.03.2019 | TR | 13.03.2019 | BG | 13.06.2019 | NO | 13.06.2019 | GR | 14.06.2019 | IS | 13.07.2019 | PT | 13.07.2019 | [2022/32] |
Former [2022/27] | HU | 08.01.2010 | |
CY | 13.03.2019 | ||
CZ | 13.03.2019 | ||
DK | 13.03.2019 | ||
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
MC | 13.03.2019 | ||
MT | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SI | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
TR | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2020/39] | CZ | 13.03.2019 | |
DK | 13.03.2019 | ||
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
MC | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SI | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
TR | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2020/17] | CZ | 13.03.2019 | |
DK | 13.03.2019 | ||
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SI | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
TR | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2020/13] | CZ | 13.03.2019 | |
DK | 13.03.2019 | ||
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SI | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2020/09] | CZ | 13.03.2019 | |
DK | 13.03.2019 | ||
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2020/04] | CZ | 13.03.2019 | |
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
IS | 13.07.2019 | ||
PT | 13.07.2019 | ||
Former [2019/52] | CZ | 13.03.2019 | |
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
PL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SK | 13.03.2019 | ||
SM | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
PT | 13.07.2019 | ||
Former [2019/49] | CZ | 13.03.2019 | |
EE | 13.03.2019 | ||
ES | 13.03.2019 | ||
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
RO | 13.03.2019 | ||
SE | 13.03.2019 | ||
SK | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
PT | 13.07.2019 | ||
Former [2019/48] | ES | 13.03.2019 | |
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
SE | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
PT | 13.07.2019 | ||
Former [2019/47] | ES | 13.03.2019 | |
FI | 13.03.2019 | ||
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
SE | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
Former [2019/46] | FI | 13.03.2019 | |
HR | 13.03.2019 | ||
IT | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
SE | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
Former [2019/39] | FI | 13.03.2019 | |
HR | 13.03.2019 | ||
LT | 13.03.2019 | ||
LV | 13.03.2019 | ||
NL | 13.03.2019 | ||
SE | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
Former [2019/38] | FI | 13.03.2019 | |
LT | 13.03.2019 | ||
SE | 13.03.2019 | ||
BG | 13.06.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
Former [2019/37] | FI | 13.03.2019 | |
LT | 13.03.2019 | ||
SE | 13.03.2019 | ||
NO | 13.06.2019 | ||
GR | 14.06.2019 | ||
Former [2019/34] | FI | 13.03.2019 | |
LT | 13.03.2019 | ||
SE | 13.03.2019 | ||
NO | 13.06.2019 | ||
Former [2019/33] | FI | 13.03.2019 | |
LT | 13.03.2019 | ||
NO | 13.06.2019 | Cited in | International search | [X]US5610144 (CAPET MARC [FR], et al) [X] 1-3,13,14 * column 99, line 33 - line 67; example 115 *; | [X]US5840758 (BROOKS CLINT D W [US], et al) [X] 1-3,13-15 * column 9 - column 10; examples 1,9-12,20-22; claims 1-13 *; | [Y]US2002019437 (BOYKIN DAVID W [US], et al) [Y] 1-4,6-9,11,13-17 * paragraphs [0002] , [0003] , [0007] - [0017] - [0019] , [0026] * * table 1 *; | [XY]EP1561463 (UNIV NORTH CAROLINA [US], et al) [X] 9 * paragraphs [0001] , [0005] - [0008] - [0064] , [0065] * * paragraph [0065] * [Y] 1-4,6-9,11,13-17; | [XY]WO2006045514 (APPLIED RESEARCH SYSTEMS [NL], et al) [X] 1,3,13,14 * page 18, paragraph last - page 19, paragraph 1; claims 1-14; compound 92 * * page 20, paragraph 4 * [Y] 2,4,6-9,11,15-17; | [X]US2007093432 (YANG LI-XI [US]) [X] 1,13,14 * page 35; compounds 2, 2a, 2b * * page 36; compounds 5,6 *; | [IY]WO2008009264 (UNIV KIEL CHRISTIAN ALBRECHTS [DE], et al) [I] 1-9,13-17 * page 2 - page 5; figures 1-4; claims 1-8 * [Y] 1-4,6-9,11; | [X]EP2009006 (TORAY INDUSTRIES [JP]) [X] 1,2,13,14 * page 127 * * table 1 *; | [XP]WO2009092358 (SCHAPER WOLFGANG [DE]) [XP] 1-3 * the whole document *; | [IP]WO2009095499 (DRITTE PATENTPORTFOLIO BETEILI [DE], et al) [IP] 1-19 * the whole document *; | [IP]WO2009095503 (DRITTE PATENTPORTFOLIO BETEILI [DE], et al) [IP] 1-19 * the whole document *; | [Y] - REHSE ET AL, "New NO Donors with Antithrombotic and Vasodilating Activities, Part 26 Amidoximes and Their Prodrugs", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE LNKD- DOI:10.1002/(SICI)1521-4184(199812)331:12<375::AID-ARDP375>3.0.CO;2-F, (19980101), vol. 331, no. 12, ISSN 0365-6233, pages 375 - 379, XP009132776 [Y] 1-4,6-9,11,13-17 * abstract * DOI: http://dx.doi.org/10.1002/(SICI)1521-4184(199812)331:12<375::AID-ARDP375>3.0.CO;2-F | [Y] - FROEHLICH A K ET AL, "Metabolism of benzamidoxime (N-hydroxyamidine) in human hepatocytes and role of UDP-glucuronosyltransferases", XENOBIOTICA, (200501), vol. 35, no. 1, ISSN 0049-8254, pages 17 - 25, XP009132770 [Y] 1-4,6-9,11,13-17 * figure 1 * | [Y] - RIGGS J R ET AL, "Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/J.BMCL.2006.01.039, vol. 16, no. 8, ISSN 0960-894X, (20060415), pages 2224 - 2228, (20060415), XP025106943 [Y] 1-4,7,9,13-17 * tables 1,2 * * Schema 1, 2 * DOI: http://dx.doi.org/10.1016/j.bmcl.2006.01.039 | [Y] - ANSEDE J H ET AL, "In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis", XENOBIOTICA, TAYLOR AND FRANCIS, LONDON, GB LNKD- DOI:10.1080/00498250500087671, (20050301), vol. 35, no. 3, ISSN 0049-8254, pages 211 - 226, XP009132798 [Y] 1-4,6,9,13-17 * the whole document * DOI: http://dx.doi.org/10.1080/00498250500087671 | [Y] - CLEMENT B ET AL, "AMIDOXIMES OF PENTAMIDINE: SYNTHESIS, TRYPANOCIDAL AND LEISHMANICIDAL ACTIVITY", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, (19850101), vol. 35, no. 7, ISSN 0004-4172, pages 1009 - 1014, XP000566459 [Y] 1-4,6-9,11,13-17 * the whole document * | [XP] - SCHADE D ET AL, "The peptidylglycine a-amidating monooxygenase (PAM): A novel prodrug strategy for amidoximes and N-hydroxyguanidines?", CHEMMEDCHEM 2009 JOHN WILEY AND SONS LTD GBR LNKD- DOI:10.1002/CMDC.200900233, (20091001), vol. 4, no. 10, pages 1595 - 1599, XP007912822 [XP] 1-19 * the whole document * DOI: http://dx.doi.org/10.1002/cmdc.200900233 | [IP] - SCHRODER A ET AL, "Arylazoamidoximes and related compounds as NO-modulators", ARCHIV DER PHARMAZIE 2010 WILEY-VCH VERLAG DEU LNKD- DOI:10.1002/ARDP.200900060, (201001), vol. 343, no. 1, pages 9 - 16, XP007912819 [IP] 1-19 * the whole document * | [A] - FRANZ ESSER ET AL, "Cyclic guanidines. Part 6. Synthesis of benzimidazoles by intramolecular vicarious nucleophilic substitution of hydrogen", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY, LETCHWORTH; GB LNKD- DOI:10.1039/A900553F, (19990101), ISSN 0300-922X, pages 1153 - 1154, XP007912863 [A] 18,19 * Schema 1 * DOI: http://dx.doi.org/10.1039/a900553f | [A] - PETERLIN-MASIC L ET AL, "Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL LNKD- DOI:10.2174/138161206775193172, (20060101), vol. 12, no. 1, ISSN 1381-6128, pages 73 - 91, XP009132773 [A] 1-17 * the whole document * DOI: http://dx.doi.org/10.2174/138161206775193172 | [A] - MARRIOTT HELEN M ET AL, "Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20061101), vol. 177, no. 9, ISSN 0022-1767, pages 6480 - 6488, XP007912841 [A] 1-17 * the whole document * | Examination | DE2640484 | US5225408 | US5587372 | - WELLER H N ET AL, "SYNTHESIS OF N-ALKYL-1,2,4-OXADIAZINONES AS ANGIOTENSIN-II (AT1) RECEPTOR ANTAGONISTS", HETEROCYCLES.INTERNATIONAL JOURNAL FOR REVIEWS AND COMMUNICATIONS IN HETEROCYCLIC CHEMISTRY, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, (19930101), vol. 36, no. 5, ISSN 0385-5414, pages 1027 - 1038, XP001007292 | by applicant | DE4321444 |